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Background: Current treatment of inflammatory bowel disease is based on the use of 
immunosuppressants or anti-inflammatory drugs, which are characterized by important side 
effects that can limit their use. Previous research has been performed by administering these 
drugs as nanoparticles that target the ulcerated intestinal regions and increase their bioavailability. 
It has been reported that silk fibroin can act as a drug carrier and shows anti-inflammatory 
properties.
Purpose: This study was designed to enhance the interaction of the silk fibroin nanoparticles 
(SFNs) with the injured intestinal tissue by functionalizing them with the peptide motif RGD 
(arginine–glycine–aspartic acid) and to evaluate the intestinal anti-inflammatory properties of 
these RGD-functionalized silk fibroin nanoparticles (RGD-SFNs) in the trinitrobenzenesulfonic 
acid (TNBS) model of rat colitis.
Materials and methods: SFNs were prepared by nanoprecipitation in methanol, and the 
linear RGD peptide was linked to SFNs using glutaraldehyde as the crosslinker. The SFNs 
(1 mg/rat) and RGD-SFNs (1 mg/rat) were administered intrarectally to TNBS-induced colitic 
rats for 7 days.
Results: The SFN treatments ameliorated the colonic damage, reduced neutrophil infiltration, 
and improved the compromised oxidative status of the colon. However, only the rats treated 
with RGD-SFNs showed a significant reduction in the expression of different pro-inflammatory 
cytokines (interleukin [IL]-1β, IL-6, and IL-12) and inducible nitric oxide synthase in comparison 
with the TNBS control group. Moreover, the expression of both cytokine-induced neutrophil 
chemoattractant-1 and monocyte chemotactic protein-1 was significantly diminished by the RGD-
SFN treatment. However, both treatments improved the intestinal wall integrity by increasing 
the gene expression of some of its markers (trefoil factor-3 and mucins).
Conclusion: SFNs displayed intestinal anti-inflammatory properties in the TNBS model of 
colitis in rats, which were improved by functionalization with the RGD peptide.
Keywords: nanoparticles, inflammatory bowel disease, silk fibroin, TNBS rat colitis, RGD
Introduction
Ulcerative colitis and Crohn’s disease (CD) are considered the two major forms of 
inflammatory bowel disease (IBD) in humans. They are characterized by chronic 
gastrointestinal inflammation with discontinuous periods of relapses and remissions. 
The etiology of this disease remains elusive. Although different theories have been 
proposed, it is mostly believed that IBD appears in genetically predisposed individuals 
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who show an exacerbated immune response in the intes-
tine toward an unknown antigen, most probably derived 
from the intestinal microbiota. Closely related to this, the 
sufferers exhibit an altered functionality of the intestinal 
epithelium barrier that leads to increased permeability to 
luminal antigens, which easily access the lamina propria 
and trigger an abnormal immune response that generates 
the chronic intestinal inflammatory process.1 For this reason, 
restoration of the immune response appears essential for the 
treatment of IBD patients. In fact, different drug strategies 
effectively counteract the exacerbated immune response in 
IBD patients. These include aminosalicylates (sulfasalazine 
or mesalazine), immunosuppressants (glucocorticoids, aza-
thioprine, methotrexate, and cyclosporine A), and biologicals 
(infliximab or adalimumab).2 However, most of these drug 
treatments can exert important side effects that may limit 
their required prolonged use.3 For this reason, there is an 
ongoing, very active search in IBD therapy for new pharma-
cological strategies that combine intestinal anti-inflammatory 
effects and safety.
A further improvement of the above-described treatment 
concept could be the administration of the anti-inflammatory 
compounds in the form of micro- and nanoparticles. In this 
regard, Lamprecht et al,4 using the trinitrobenzenesulfonic 
acid (TNBS) model of rat colitis, observed increased accu-
mulation and adhesion of fluorescent polystyrene particles 
in the ulcerated areas of the affected tissue, with respect to 
non-ulcerated control tissue. This adhesion was reported to be 
size dependent, the best results being obtained with 100-nm 
particles. Considering this, the same group designed a system 
to transport drugs such as tacrolimus,5 low-molecular weight 
heparin,6 and rolipram7 on PLGA nanoparticles. Similarly, 
other studies have assayed the release of dexamethasone 
from poly-d,l-lactic acid particles for the treatment of TNBS 
rat colitis8 or dextran sodium sulfate-induced intestinal 
inflammation in mice.9 All these studies revealed that the 
therapeutic effect of the assayed drugs was improved when 
they were loaded in nanoparticles, most probably due to the 
targeting to the ulcerated areas.4
Nanoparticles of a very different nature could be used 
as carriers for the delivery of therapeutic compounds. 
Among them, particles obtained from natural polymers 
are very interesting since they are biocompatible and 
biodegradable.10,11 An interesting option is the use of silk 
fibroin nanoparticles (SFNs). Silk fibroin (SF) is the fibrous 
protein that constitutes the fiber secreted by the silkworm 
Bombyx mori to make a cocoon for its pupation. This 
material has many interesting advantages as a scaffold 
for growing different cell lines, including stem cells.12–14 
Moreover, SF has been shown to be an excellent matrix 
for controlled drug delivery, being processed as nano- or 
microparticles by well-known procedures in aqueous or ionic 
liquid solution.15,16 Fibroin particles have been fabricated by 
ultrasound vibration,17 spray drying,18 and desolvation.19,20 
In addition to its role as a drug carrier, fibroin itself possesses 
bioactive properties. In this regard, the peptides derived 
from its hydrolysis have displayed interesting properties; 
for example, they are able to stimulate glucose transport in 
both normal and 3T3-L1 insulin-resistant adipocytes21 and 
activate fibroblast proliferation in wound healing models.22 
The anti-inflammatory properties of fibroin-derived peptides 
have also been described. Thus, Kim et al23 showed that SF 
peptides exhibited anti-inflammatory activity in the mice 
edema model of inflammation induced by topical treatment 
of mouse ears with 12-O-tetradecanoylphorbol-13-acetate 
(TPA). This was related to their ability to prevent the 
increases in the levels of interleukin (IL)-6, IL-1β, tumor 
necrosis factor-α, and cyclooxygenase-2 induced by TPA 
administration. More recently, Lozano-Pérez et al24 reported 
that fibroin nanoparticles loaded with resveratrol have 
intestinal anti-inflammatory effects in the TNBS model of 
rat colitis, when administered intracolonically. In this study, 
SFNs administered alone exerted beneficial effects in this 
experimental model of colitis. In consequence, SFNs rep-
resent an interesting option for IBD therapy, since they 
combine the anti-inflammatory properties of the material 
together with the possibility of targeting them to the inflamed 
area. In addition, the effect of fibroin on wound healing, 
as evidenced in vivo,25 may promote its use to treat these 
pathological intestinal conditions. Moreover, it has been 
proposed that the molecular mechanisms involved in this 
effect are related to the ability of fibroin (and also sericin) to 
induce the up-regulation and phosphorylation of the protein 
c-Jun that has a role in keratinocyte migration in wound 
repair.26 This could have a positive impact on the altered 
epithelial barrier function described for human IBD. It is 
of note that mucosal healing in IBD has been associated 
with more effective disease control and improved quality of 
life in these patients, and consequently it has become a key 
objective in IBD therapy.27
Considering all the above, it seems interesting to fur-
ther improve the intestinal anti-inflammatory properties 
of SFNs in relation to their potential use in human IBD 
therapy. With this aim, this study explores the possibility of 
enhancing the interaction of nanoparticles with the injured 
tissue, by functionalizing them with the peptide motif RGD 
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(arginine–glycine–aspartic acid). The anticipated improve-
ment in the intestinal anti-inflammatory properties exerted by 
these RGD-functionalized silk fibroin nanoparticles (RGD-
SFNs) was tested in the TNBS model of rat colitis – a widely 
used model of colitis that resembles human IBD and in which 
SFNs have already shown efficacy and a lack of toxicity.24 
RGD is a well-known motif of adhesion of integrins of the 
cell surface to the extracellular matrix of connective tissue, 
which can be covalently bound to the fibroin nanoparticle 
surface and is extensively used to functionalize different 
matrices of drug carriers.24,28 The rationale of this approach is 
based on the fact that integrins are highly expressed in human 
intestinal inflammation, since they are clearly involved in the 
recruitment of mononuclear cells and leukocyte populations 
from the bloodstream into the inflamed intestine, and are thus 
considered to play a critical role in its pathogenesis.29–31
Materials and methods
Materials
SF was obtained from silkworms bred in the sericulture 
facilities of the IMIDA (Murcia, Spain). All other reagents, 
including the linear RGD peptide (Gly-Arg-Gly-Asp-
Ser), were purchased from Sigma-Aldrich Quimica 
(Madrid, Spain), unless otherwise stated. Purified water 
(18.2 MΩ⋅cm at 25°C) was obtained from a Millipore 
Direct-Q1 ultra-pure water system (EMD Millipore, Billerica, 
MA, USA). All other chemicals and solvents of analytical 
grade were used without further purification.
Preparation of reconstituted liquid SF
Silkworm cocoons were boiled twice for 45 min in aqueous 
0.02 N Na
2
CO
3
 and rinsed carefully with water to extract 
the glue-like sericin proteins. Then, the raw SF was dried at 
room temperature for 72 h. Subsequently, it was dissolved 
at 10% (w/v) in Ajisawa’s reagent32 – composed of 
CaCl
2
:ethanol:H
2
O (1:2:8, molar ratio) – for 6 h at 70°C. This 
solution was then dialyzed for 48 h against distilled water to 
remove CaCl
2
, small molecules, and some impurities, using 
a cellulose semi-permeable membrane (cutoff 3.5 kDa).
Preparation of SFNs
The SFNs were prepared by nanoprecipitation in methanol.20 
In brief, 10 mL of a 4% (w/v) aqueous solution of SF was 
dropped into 90 mL of cold methanol and stirred gently for 
2 h. Afterward, the nanoparticles were collected by centrifu-
gation at 18,500× g for 15 min, at 4°C, in an Eppendorf 5810R 
centrifuge equipped with an F-34-6-38 rotor (Eppendorf, 
Hamburg, Germany). They were washed three times with 
ultrapure water, lyophilized, and kept in a desiccator at room 
temperature until use.
Nanoparticles functionalization with 
linear RGD peptide
Characterization of SFNs previous to 
functionalization
The SFNs were characterized in terms of the parameters 
considered fundamental for a proper design of the following 
functionalization.
Nanoparticle size was determined in a phosphate-buffered 
suspension (pH 7.4) by dynamic light scattering (DLS) 
measurement with a Brookhaven 90Plus DLS instrument 
(Brookhaven Instruments Corporation, Holtsville, NY, 
USA), by means of photo-correlation spectroscopy. The final 
data were obtained from a statistical analysis of ~10 runs.
Field emission scanning electron microscopy (FESEM) 
was also used to visualize the nanoparticles. A 50 μL of 
SFN suspension (in water) was cast on to a glass wafer, 
dried overnight, and coated with Pd. The nanoparticles were 
observed by FESEM using a MERLIN™ VP COMPACT 
scanning electron microscope (Carl Zeiss Microscopy S.L., 
Oberkochen, Germany). Images detailing the morphology 
were taken using an SE2 detector, under an accelerating 
voltage of 15 kV (working distance =9.3 mm and aperture 
size =30.00 μm).
In SFNs produced by the method of Zhang et al,33 the Lys 
(CH
2
)
4
-NH
2
 groups are exposed on the surface. The nanopar-
ticle amino content was measured by the orange II spectro-
photometric assay.34,35 Nanoparticles (1.5 mg) were dispersed 
in 1.5 mL of 14 mg/mL orange II acidic solution (pH 3) and 
maintained under magnetic stirring for 30 min at 40°C. The 
nanoparticles were then precipitated and washed with acidi-
fied water until all the unbound dye was removed. Then, an 
alkaline solution (pH 12) was added and the bound dye was 
desorbed from the surfaces of the nanoparticles. After nano-
particle removal from the medium, the pH was adjusted to 3 
and the amount of desorbed dye was measured at a wavelength 
of 480 nm, with a Varian Cary 50 UV/Vis spectrophotometer 
(Agilent Technologies, Inc., Santa Clara, CA, USA).
Functionalization with linear RGD
The linear RGD peptide was linked to the SFNs using glu-
taraldehyde as the crosslinker. Briefly, in the first step of the 
process, 83 nmol of glutaraldehyde was added per mg of SFNs 
(previously dispersed in 10 mM phosphate buffer at pH 7.4). 
The suspension was stirred for 90 min to complete the first 
coupling reaction. Then, the nanoparticles were centrifuged 
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and washed with buffered solution to remove the excess 
reactant. In the second step of the process, 16 nmol of RGD 
peptide was added to the glutaraldehyde-activated SFNs and 
the mixture was stirred for 90 min. Then, the suspension was 
centrifuged and washed three times with buffered solution. 
The whole process is summarized in Figure 1.
Evaluation of the efficiency of the functionalization 
process
The efficiency of the functionalization process was evaluated 
by measuring the RGD peptide present in the supernatant of 
the reaction by the fluorescamine fluorescence spectroscopy 
assay.36 The amount of linked RGD was calculated as 
the difference between the fluorescence intensity of the 
control, corresponding to 100% of the RGD in the reaction 
mixture, and the fluorescence intensity of the supernatant. 
The hydrodynamic diameters of the intermediate step 
of glutaraldehyde functionalization and the final step of 
RGD-functionalized SFNs (RGD-SFNs) were obtained 
through DLS measurement, as reported earlier. The data 
referring to each functionalization step were compared with 
those referring to the hydrodynamic diameter of the naked 
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Figure 1 Functionalization of SFNs with linear RGD peptides through glutaraldehyde crosslinking.
Abbreviations: SFNs, silk fibroin nanoparticles; RGD, arginine–glycine–aspartic acid.
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nanoparticles to demonstrate the efficiency of the function-
alization process.
In vivo evaluation of the bioactivity of 
functionalized SFNs in the TNBS model 
of rat colitis
This study was performed according to the “Guide for 
the Care and Use of Laboratory Animals” of the National 
Institute of Health. The experimental protocol was autho-
rized by the ethics committee on Laboratory Animals of the 
University of Granada (Spain) (reference number CEEA-
2010-286). Female Wistar rats (180–200 g) were purchased 
from Janvier Labs (St Berthevin Cedex, France). They were 
housed in Makrolon cages and kept in an air-conditioned 
atmosphere with a 12-h light–dark cycle, with free access 
to tap water and food. The rats were distributed into four 
groups (n=10). An untreated TNBS control group and a 
non-colitic group were included for reference and were 
given – intrarectally – the same volume of the vehicle used 
to administer the test products (0.2 mL of phosphate-buffered 
saline). The treatments tested were SFNs (1 mg/rat) and 
SFNs functionalized with linear RGD (1 mg/rat), in 0.2 mL 
of phosphate-buffered saline.
Colonic inflammation was induced in the control and 
treated groups as described by Camuesco et al.37 Briefly, rats 
were fasted overnight, anesthetized with isoflurane (Isoflo®; 
Esteve, Barcelona, Spain), and 10 mg of TNBS dissolved 
in 0.25 mL of 50% ethanol (v/v) was instilled by means of 
a Teflon cannula inserted 8 cm through the anus. The rats 
were kept in a head-down position until they recovered 
from the anesthesia and were put back into their cages. 
Rats from the non-colitic group received – intrarectally – 
0.25 mL of phosphate-buffered saline. The rats were 
given – intrarectally – the treatments once per day thereafter 
until being sacrificed with an overdose of isoflurane 7 days 
later. The animal body weights, occurrence of diarrhea, and 
water and food intake were recorded daily throughout the 
experiment. After sacrifice, the colon was removed asepti-
cally, opened, and cleaned of its luminal contents with cold 
saline. Then, its length and weight were measured. The 
macroscopic visible damage was scored on a 0–10 scale by 
two independent observers, following the criteria described 
before.37 Representative colon samples were taken from an 
inflamed region adjacent to the gross macroscopic damage, 
fixed in 4% buffered formaldehyde, and embedded in paraffin. 
Equivalent colonic segments were also obtained from the 
non-colitic group: 5-μm paraffin sections were cut at different 
levels and stained with hematoxylin and eosin. The histologic 
damage was evaluated by two pathologists blinded for the 
study following the criteria reported by Arribas et al,38 and 
images were taken by standard light microscopy using 
an Olympus CX41 microscope (Olympus Iberia, S.A.U., 
Barcelona, Spain). The colon was subsequently minced, 
aliquoted, and kept frozen at −80°C until biochemical deter-
minations and RNA extraction were performed.
Evaluation of colonic damage
Myeloperoxidase (MPO) activity was measured with the 
technique described by Krawisz et al,39 and the results were 
expressed as MPO units per gram of wet tissue; one unit 
of MPO activity was defined as that degrading 1 μmol of 
hydrogen peroxide/min at 25°C. The total glutathione (GSH) 
content was quantified with the recycling assay described 
by Anderson,40 and the results were expressed as nmol/g 
wet tissue.
Analysis of gene expression in colonic 
samples by real-time quantitative 
polymerase chain reaction (RT-qPCR)
Total RNA from the colonic samples was isolated using TRI 
Reagent®, according to the manufacturer’s instructions. After 
quantifying the RNA, using a Thermo Scientific NanoDrop™ 
2000 spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA, USA), 2 μg of RNA was reverse transcribed 
using oligo(dT) primers (Promega, Southampton, UK). 
Subsequently, 20 ng of complementary DNA was taken 
for real-time quantitative PCR amplification and detec-
tion, which was accomplished on optical-grade 48-well 
plates in an Eco™ Real-Time PCR System (Illumina, San 
Diego, CA, USA) with the KAPA SYBR® FAST qPCR 
Master Mix (Kapa Biosystems, Inc., Wilmington, MA, 
USA) and specific primers at their annealing tempera-
ture (Table 1). The expression of the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
measured to normalize messenger RNA (mRNA) expres-
sion. The mRNA relative quantitation was calculated with 
the ∆∆Ct method.
statistics
All results are expressed as the mean ± standard error of the 
mean, except for non-parametric data (scores) – which are 
expressed as the median (range) and were analyzed using 
the Mann–Whitney U-test. Differences between mean values 
were tested for statistical significance using a one-way 
analysis of variance and post hoc least significance tests. All 
statistical analyses were performed with GraphPad Prism 
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version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA), 
with statistical significance set at P,0.05.
Results
Nanoparticles functionalization with 
the linear RGD peptide
Nanoparticle characterization
The hydrodynamic diameter of the nanoparticles was mea-
sured by DLS analysis, and these data were used as the control 
in the following measurements of the diameter of functional-
ized nanoparticles. The diameter distribution is reported in 
Figure 2. The diameter of the nanoparticles varied from 60 to 
100 nm, showing a low polydispersity index. The percentage 
of 450-nm nanoparticles, which were probably produced by 
aggregation phenomena during the lyophilization process used 
for nanoparticle storage, was very low. The values are almost 
identical to those described previously in the literature.19,33,41
The FESEM images of the RGD-SFNs show that the 
silk particles were globular granules, quite homogeneous in 
size (Figure 2). As can be seen in the images, no apparent 
differences in the particle surface were observed, due to the 
relatively small size of the attached molecules in comparison 
with the overall size of the nanoparticles.
The orange II spectrophotometric assay was used to 
determine the amount of amino groups on the nanoparticle 
surface. This measurement was important in order to adjust 
the amounts of reactive groups in the functionalization 
process and to avoid massive crosslinking between nano-
particles. The compound orange II is able to bind to surface 
amino groups in a pH-dependent way. The method represents 
an indirect determination of the amino groups since the 
spectrophotometric analysis is carried out on the compound 
recovered after breaking such pH-dependent interactions. 
The advantage of this method is that no interference due to 
the presence of the nanoparticle is possible. The assay was 
highly reproducible, giving the proportion of amino groups 
as 80 nmol/mg of SFNs.
Nanoparticles functionalization with the linear RGD 
peptide
The functionalization process consisted of a two-step pro-
tocol, in the first of which the Lys amino groups on the 
nanoparticle surface were previously functionalized with 
glutaraldehyde. In the second step, the RGD peptide was 
added. The RGD peptide possesses a primary amino group 
that is able to react with glutaraldehyde. All the steps were 
carried out in 10 mM phosphate buffer (pH 7.4), since it 
allows good stability of the nanoparticle suspension and 
maintains a low degree of protonation of the reactive amino 
groups. After the reaction, the functionalized nanoparticles 
were washed with fresh buffer to eliminate any residual 
reactant (glutaraldehyde).
The efficiency of the functionalization process was evalu-
ated by measuring the residual peptide in the supernatant of 
the reaction mixture, with the fluorescamine spectrofluori-
metric assay.36 The results show that the functionalization 
protocol led to a peptide linkage efficiency of 65%.
Small changes in the hydrodynamic diameter of the nano-
particles were apparent from the DLS measurements made 
after every reaction step, confirming the successful binding 
of the biomolecules through the glutaraldehyde crosslink. 
The changes in the size distribution of the nanoparticles 
during the process are exhibited in Figure 2. The size distri-
bution was not changed significantly by the first step of the 
process. In contrast, Figure 2 shows how it changed after 
peptide binding: the increase in the hydrodynamic diameter 
of the nanoparticles constitutes evidence of the efficiency of 
the functionalization process.
Also, the Z-potential of the nanoparticles before and after 
functionalization was measured at different pH values to better 
characterize the changes in the surface after RGD binding. 
In Figure 2F, a significant difference in the Z-potential 
can be observed between the synthesized SFNs and the 
Table 1 Primer sequences used in real-time PCR assays in 
colonic tissue
Gene Sequence 5′–3′ Annealing 
temperature 
(°C)
GAPDH FW: ccaTcaccaTcTTccaggag
rV: ccTgcTTcaccaccTTcTTg
60
IL-1β FW: gaTcTTTgaagaagagcccg
rV: aacTaTgTcccgaccaTTgc
59
IL-6 FW: cTTccagccagTTgccTTcTTg
rV: TggTcTgTTgTgggTggTaTcc
60
IL-12 FW: acgcTaccTccTcTTcTTg
rV: aTgTcgTccgTggTcTTc
60
CINC-1 FW: ccgaagTcaTagccacacTcaag
rV: TcaccagacagacgccaTcg
60
MCP-1 FW: TcTTccTccaccacTaTgc
rV: TcTccagccgacTcFaTTg
60
iNOS FW: aagagacgcacaggcagagg
rV: agcaggcacacgcaaTgaTg
59
TFF-3 FW: aTggagaccagagccTTcTg
rV: acagccTTgTgcTgacTgTa
60
MUC-2 FW: accaccaTTaccaccaccTcag
rV: cgaTcaccaccaTTgccacTg
60
Abbreviations: PCR, polymerase chain reaction; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; IL, interleukin; CINC-1, cytokine-induced neutrophil 
chemoattractant-1; MCP-1, monocyte chemotactic protein-1; iNOS, inducible nitric 
oxide synthase; TFF, trefoil factor; MUC, mucin.
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RGD-functionalized particles (especially at acidic pH values), 
due to the presence of the RGD molecules on the surface.
Intestinal anti-inflammatory activity of 
RGD-SFNs
The objective of this assay was to examine if the func-
tionalization of the SFNs resulted in an additional anti- 
inflammatory effect when compared with the bare 
nanoparticles. The results show that both types of SFNs 
displayed intestinal anti-inflammatory effects. This was 
demonstrated macroscopically since the colonic weight/
length ratio was significantly reduced in comparison with the 
colitic control group (Table 2), suggesting a reduction of the 
edema related to the TNBS-induced inflammatory process. 
Moreover, the two treatments also produced a significant 
decrease in the extension of the damaged areas in the colon, 
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Figure 2 Morphological characterization of the nanoparticles.
Notes: Hydrodynamic diameter distribution of (A) naked SFNs before functionalization; (B) glutaraldehyde-activated SFNs; and (C) SFNs with RGD bound on the surface 
(the insets represent the surface modifications). FESEM images of (D) naked SFNs before functionalization and (E) SFNs with RGD bound on the surface (scale bar 500 nm, 
magnification 17.25 K). (F) Z-potential analysis of SFNs and RGD-SFNs.
Abbreviations: SFNs, silk fibroin nanoparticles; RGD, arginine–glycine–aspartic acid; FESEM, field emission scanning electron microscopy; RGD-SFNs, RGD-functionalized 
sFNs.
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since the treated groups had lower values of the macroscopic 
score than the control colitic group (Table 2). Hence, the 
administration of nanoparticles facilitated the recovery of 
the damaged colon. This observation was confirmed after 
the histologic evaluation. The TNBS produced a significant 
disruption of the colonic mucosa – affecting .80% of the 
surface, involving all the layers – and was characterized by 
epithelial ulceration, crypt hyperplasia, and intense goblet 
cell depletion. Severe granulocyte infiltration was observed, 
mainly involving neutrophils in the lamina propria. The 
grade of the lesion was scored as severe or very severe 
(31 [20–46]) (Figure 3). Both SFN treatments significantly 
enhanced the intestinal cytoarchitecture by lessening the 
damaged surface area – to ~25% – and the transmural 
involvement, thus improving the reepithelialization. In addi-
tion, the inflammatory infiltrate was slight to moderate with 
a patchy distribution and the goblet cells appeared to be in 
the process of recovery; some of them had replenished their 
mucin content. Therefore, the microscopic scores assigned 
to these groups were significantly lower than for the control 
colitic group (14 [8–20] [SFNs] and 14 [4–22] [RGD-SFNs], 
P,0.05) (Figure 3).
The biochemical parameters evaluated in the colon 
confirmed the intestinal anti-inflammatory effect exerted by 
both types of SFNs, bare or functionalized with RGD. Thus, 
MPO activity was significantly reduced in the treated colitic 
groups when compared with control colitic rats, probably 
due to the significant reduction of the leukocyte infiltration 
into the inflamed intestinal tissue that was observed and that 
characterizes this experimental model of colitis37 (Table 2). 
However, for the colitic group that received the RGD-SFNs, 
the reduction in this enzyme activity was greater than that 
obtained with the bare nanoparticles (Table 2). TNBS colitis 
is also characterized by an intense oxidative insult that 
depletes the antioxidant peptide GSH,37,42,43 but the nano-
particles treatments managed to increase the colonic GSH 
content, thus diminishing the severity of the oxidative stress 
that characterizes the inflamed colon (Table 2).
The colonic expression of the pro-inflammatory cytokines 
IL-1β, IL-6, and IL-12 was significantly greater in the colitic 
groups than in the non-colitic rats, indicating an altered 
immune response induced by the instillation of TNBS 
(Figure 4). However, only the colitic rats treated with RGD-
SFNs showed a significant reduction in the expression of these 
three cytokines in comparison with colitic rats from the con-
trol group or those that received the bare SFNs (Figure 4).
Colonic inflammation was also associated with an 
increased expression of the chemokine cytokine-induced 
neutrophil chemoattractant (CINC)-1, which promotes 
the recruitment and later activation of neutrophils in the 
inflamed area, and of the monocyte chemotactic protein 
(MCP)-1 that favors the chemotaxis of monocytes and their 
subsequent differentiation into macrophages in the inflamed 
tissue (Figure 5). Similarly to the previous result, only the 
RGD-SFNs managed to significantly reduce the expression 
of both CINC-1 and MCP-1 in comparison with the colitic 
control group (Figure 5).
Moreover, TNBS instillation also resulted in an increased 
colonic expression of iNOS, in accordance with previous 
results obtained in experimental models of rodent colitis.44,45 
Again, it is of note that only the colitic rats treated with 
RGD-SFNs showed a significantly reduced expression of 
colonic iNOS when compared with the control colitic groups, 
whereas the bare nanoparticles only produced a tendency 
of the expression to decrease, but no statistical differences 
were found (Figure 5).
Finally, when different markers related to the integrity of 
the intestinal epithelium were evaluated, the TNBS intesti-
nal damage was characterized by reduced expression of the 
intestinal trefoil factor (TFF)-3, a bioactive peptide involved 
in epithelial protection and repair, and the mucin MUC-2, 
the primary constituent of the mucus layer in the colon 
(Figure 6).46 Both treatments with SFNs (RGD functional-
ized and bare) increased the expression of TFF-3 and MUC-2 
(Figure 6), thus contributing to the restoration of the epithelial 
barrier and the preservation of the mucus layer that covers 
Table 2 Effects of RGD-SFNs (1 mg/rat, intrarectally) on the colonic macroscopic damage score, weight/length ratio, MPO activity, 
and gsh content in TNBs experimental rat colitis
Group (n=10) Damage score (0–10) Weight/length (mg/cm) MPO (mU/g tissue) GSH (nmol/g tissue)
Non-colitic 0a 66.2±4.4a 18.7±5.9a 2076±86a
colitic control 7.5 (6–8)b 228.4±16.1b 230.3±23.4b 791±66b
sFNs 5.0 (4–8)c 158.9±31.2c 143.0±27.3c 1487±261c
RGD-SFNs 5.5 (4–7)c 146.1±29.6c 49.9±10.7d 1191±188c
Notes: Score data are expressed as the median (range) and the rest of the data as the mean ± SEM. Groups with different letters differ statistically (P,0.05).
Abbreviations: RGD, arginine–glycine–aspartic acid; SFNs, silk fibroin nanoparticles; RGD-SFNs, RGD-functionalized silk fibroin nanoparticles; MPO, myeloperoxidase; 
GSH, glutathione; TNBS, trinitrobenzenesulfonic acid; SEM, standard error of the mean.
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and protects the integrity of the epithelium and accelerating 
the recovery of the damaged intestinal mucosa.
Discussion
Currently, there is a demand for new therapeutic strategies for 
human IBD. Although many different drug treatments with 
reputed efficacy against this intestinal condition are avail-
able, most of them are not devoid of significant side effects 
that limit their use – especially when they are prescribed 
chronically, as required for most patients. Moreover, 
complicated dosing schedules and a somewhat excessive 
cost can also make their long-term usage problematic.3 
A previous study with the TNBS experimental model of 
rat colitis demonstrated that SFNs could be used as carri-
ers for the controlled release of active drugs, such as res-
veratrol, used against intestinal inflammation.24 In the same 
study, the bare SFNs also exerted beneficial effects when 
administered intrarectally, showing an efficacy similar to that 
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Figure 3 Histologic sections of colon stained with hematoxylin and eosin.
Notes: (A) Non-colitic; (B) colitic control; (C) SFNs; and (D) RGD-SFNs. (E) Microscopic score assigned according to the criteria previously described.38 The data are 
expressed as the median (range); groups with different letters differ statistically (P,0.05).
Abbreviations: SFNs, silk fibroin nanoparticles; RGD, arginine–glycine–aspartic acid; RGD-SFNs, RGD-functionalized SFNs.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
5.
21
0.
59
.2
10
 o
n 
13
-D
ec
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5954
Rodriguez-Nogales et al
?
?
? ?
?
??????????? ?????????????? ???? ????????
?????
????
????
????
?
?
?
?
?
?
?
?
?
?
?
??????????? ?????????????? ???? ????????
????
????
????
????
?
?
?
??
??
??
??? ????β??
??
?
?
?
?
?
?
??????????? ?????????????? ???? ????????
????
????
????
?
Figure 4 Effects of RGD-SFNs (1 mg/rat, intrarectally) in TNBS rat colitis on colonic gene expression of the cytokines (A) IL-1β, (B) IL-6, and (C) IL-12, analyzed by 
real-time PCR.
Notes: The data are expressed as the mean ± SEM. Groups with different letters differ statistically (P,0.05).
Abbreviations: RGD, arginine–glycine–aspartic acid; SFNs, silk fibroin nanoparticles; RGD-SFNs, RGD-functionalized SFNs; TNBS, trinitrobenzenesulfonic acid; 
IL, interleukin; PCR, polymerase chain reaction; SEM, standard error of the mean.
of dexamethasone, a glucocorticoid that is currently used in 
human IBD therapy.2 In consequence, fibroin nanoparticles 
should not be considered just as inert carriers when used in 
intestinal inflammation therapy. Furthermore, it has been 
demonstrated that SFNs have the special ability to target 
ulcerated and damaged areas of the intestine,4 which could 
contribute to their beneficial local effects on these intestinal 
conditions. So, the design of additional strategies to enhance 
their intestinal anti-inflammatory properties is of great 
interest. In this way, the drugs could be used at lower doses 
while keeping/enhancing their efficacy, but improving their 
pharmacological profile and reducing the side effects.
With this aim, SFNs were functionalized with RGD, a 
motif of adhesion of integrins of the cell surface to the extra-
cellular matrix of connective tissue. It has been proposed that 
integrins may play a key role in the pathogenesis of IBD, 
since they are highly expressed in the gut of IBD patients 
and are involved in leukocyte recruitment to the inflamed 
intestinal tissue.29 In fact, they have been considered an 
interesting target for IBD treatment, and antibodies directed 
to integrins, such as natalizumab and vedolizumab, have 
shown efficacy in human clinical trials.47
Nanoparticle functionalization with the RGD peptide 
was successfully carried out using glutaraldehyde as the 
homobifunctional crosslinker. This reaction was carefully 
optimized in terms of the reactant/SFNs ratio. In this way, 
no aggregation due to nanoparticles crosslinking was 
observed.
The SFNs possess a very negatively charged surface 
in their naked state (before functionalization). The shift of 
the surface potential to less negative values, found after 
functionalization, indicates that the adhesive properties of 
the material per se could be enhanced by a masking of the 
negative charge due to the presence of the peptide.
This study confirms the intestinal anti-inflammatory prop-
erties of the SFNs in the TNBS model of experimental colitis, 
as evidenced both macroscopically and biochemically, even 
at 1 mg/rat, a dose lower than that used in the previous study 
(8 mg/rat).24 However, the incorporation of RGD into the 
SFNs resulted in beneficial effects additional to those shown 
by bare SFNs, as demonstrated when the colonic tissue was 
evaluated biochemically. In this regard, colonic MPO activity 
is related to neutrophil infiltration and has long been used 
as a marker of the severity of the intestinal inflammatory 
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process.44,48 Supporting this, intestinal inflammation has 
been widely proposed to start with leukocyte infiltration into 
the lamina propria, which facilitates the chronicity of the 
inflammatory response.49 For this reason, inhibition of MPO 
activity in the colon can be considered as a manifestation of 
the intestinal anti-inflammatory effect of a given treatment.50 
Thus, in this study, when MPO activity was assayed in the 
colon of colitic rats, the lowest values were observed in rats 
treated with RGD-SFNs, being statistically different from the 
values obtained with SFNs (P,0.05). This agrees with the 
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Figure 6 Effects of RGD-SFNs (1 mg/rat, intrarectally) in TNBS rat colitis on colonic gene expression of (A) the trefoil factor TFF-3 and (B) the mucin MUC-2.
Notes: The data are expressed as the mean ± SEM. Groups with different letters differ statistically (P,0.05).
Abbreviations: RGD, arginine–glycine–aspartic acid; SFNs, silk fibroin nanoparticles; RGD-SFNs, RGD-functionalized SFNs; TNBS, trinitrobenzenesulfonic acid; PCR, 
polymerase chain reaction; SEM, standard error of the mean.
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Figure 5 Effects of RGD-SFNs (1 mg/rat, intrarectally) in TNBS rat colitis on colonic gene expression of the chemokines (A) CINC-1 and (B) MCP-1 and of (C) the inducible 
enzyme iNOS, analyzed by real-time PCR.
Notes: The data are expressed as the mean ± SEM. Groups with different letters differ statistically (P,0.05).
Abbreviations: RGD, arginine–glycine–aspartic acid; SFNs, silk fibroin nanoparticles; RGD-SFNs, RGD-functionalized SFNs; TNBS, trinitrobenzenesulfonic acid; IL, 
interleukin; CINC-1, cytokine-induced neutrophil chemoattractant-1; MCP-1, monocyte chemotactic protein-1; iNOS, inducible nitric oxide synthase; PCR, polymerase 
chain reaction; SEM, standard error of the mean.
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histologic evaluation, although no statistical differences 
were observed between the two treated groups (P.0.05). 
The higher efficacy could be attributed to the differences 
detected when the chemokines CINC-1 and MCP-1 were 
evaluated. In fact, only the treatment with RGD-SFNs was 
able to significantly decrease their expression in the inflamed 
colon. CINC-1, a functional analog of IL-8, is involved 
in neutrophil recruitment and activation.51 Similarly, the 
chemokine MCP-1 contributes to the inflammatory process 
by promoting the recruitment to sites of injury of monocytes, 
memory T-cells, dendritic cells, and, indirectly, neutrophils.52 
Moreover, the significant reduction in the expression 
of MCP-1 could account for the lower infiltration and the 
subsequent amelioration of the macrophage activation of the 
colon damage. Furthermore, this may be related to a reduced 
expression of the inducible enzyme iNOS, which was only 
seen in the RGD-SFN-treated group, since macrophages are 
considered one of the main sources of iNOS expression in 
inflammatory conditions.45
The greater inhibitory effect exerted by the RGD-SFNs 
on leukocyte infiltration could also explain the differences 
observed in the pro-inflammatory cytokines IL-1β, IL-6, 
and IL-12 among the groups, thus revealing an improve-
ment in the altered immune response. It is of note that the 
expression of each of these cytokines has been found to be 
up-regulated in human IBD, their effects on the intestine 
being closely associated with the generation of colonic 
damage.53
Both treatments resulted in a partial amelioration of 
some biochemical markers related to epithelial integrity, 
which could also effectively account for their intestinal 
anti-inflammatory effect. Thus, both treatments signifi-
cantly increased the expression of the mucin MUC-2, one 
of the major components of the intestinal mucus layer,54 
and of TFF-3, one of the peptides involved in epithelial 
protection and repair.55 In consequence, the development 
of the mucus-secreting layer that covers the epithelium and 
acts as a physical barrier may have protected its integrity 
and accelerated the recovery of the injured colonic tissue, 
which was also appreciated in the histologic evaluation. 
In this regard, it has been proposed that one of the early 
events in gut inflammation is a defect in the epithelial bar-
rier function, which promotes the entry of luminal antigens 
that facilitate an exaggerated immune response. So, the 
speeding-up of mucosal restoration appears to be of special 
significance. In fact, healing of the inflamed mucosa is now 
emerging as a key goal and a tool to predict clinical success 
in the management of IBD.56
Conclusion
Fibroin nanoparticles have been used successfully in this 
study as carriers for the RGD peptide. The functionalization 
process has been optimized, and covalent binding – through 
glutaraldehyde crosslinking – with a linear RGD peptide 
has been obtained. These nanocarriers have been tested and 
compared in the treatment of intestinal inflammation in rats. 
The treatments involving the daily administration of fibroin 
nanoparticles by the intrarectal route, at a dose of 1 mg/rat, 
showed a beneficial effect in the model of experimental colitis 
induced by TNBS in rats. When considering the impact on 
the altered immune response that characterizes the intestinal 
inflammatory process, this effect was clearly improved when 
the nanoparticles were functionalized with RGD.
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